Supha Pharmachem Ltd
- Market cap
- ₹ 22 Cr.
- P/E
- 10.3x
- P/B
- 0.33x
- 52-week range
- 0.23 – 1.66
- ROE
- 5%
- Dividend yield
- 0%
- Debt / equity
- 26.01
- Sector
- Commercial Services & Supplies
- Industry
- Trading & Distributors
- Listed on
- BSE
About
Supha Pharmachem Limited, formerly Remedium Lifecare Limited, is an India-based pharmaceutical and specialty chemicals company engaged in trading and distribution of raw materials for the pharmaceutical industry. The Company is engaged in the business of trading in advanced pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and other pharma products used viz. Isopropyl Alcohol (IPA) ,Cyclohexane, Diisopropyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Methylene Dichloride, Potassium Carbonate Powder, Sodium Bicarbonate, Potassium Hydroxide Flakes, Sodium Chloride (common salt), Sodium Carbonate (soda ash), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, and Trimethyl Sulfoxonium Iodide (TMSI).
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Trading & Distributors: 197 companies →Supha Pharmachem Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)10.3 against a typical 28.5: cheaper than most peers (1st = cheapest).42nd of 186
- Share price, 3 months−24.2% against a typical −4.9%.147th of 169
- Size₹ 22.1 Cr. market value against a typical ₹ 26.8 Cr. (1st = largest).97th of 183
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|
| Sales | 264 | 113 | 111 |
| Expenses | 265 | 112 | 104 |
| Operating Profit | −0 | 2 | 7 |
| OPM % | −0.2% | 1.7% | 6.7% |
| Other Income | 1 | 3 | 3 |
| Interest | 2 | −0 | 0 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | −1 | 6 | 10 |
| Tax % | 45.7% | 18.6% | 17.3% |
| Net Profit | −2 | 5 | 9 |
| EPS in Rs | −0.02 | 0.05 | 0.1 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- −40%
- 3 Years
- −86%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Supha Pharmachem Ltd | ₹ 0.25 | ₹ 22 Cr. | 10.3x | 0.3x | 5% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Ashish Dinanath Parkar
- Chief Financial Officer
- Adarsh Deepak Munjal
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.